Sativex

Property	Information
Drug Name	Sativex (Nabiximols)
FDA Approval	Not FDA-approved in the United States; approved in several countries for spasticity due to multiple sclerosis
Used for	Investigational use in glioblastoma for potential direct anti-tumor effects and symptom management
Clinical Trial Phase	Phase 2 clinical trial in 2021 indicated for glioblastoma
Clinical Trial Explanation	Not specified
Common Side Effects	Fatigue, dizziness, nausea, mouth irritation
OS without	Not specified
OS with	The 2021 trial reported an increase in overall survival for glioblastoma patients treated with Sativex in combination with temozolomide compared to temozolomide alone
PFS without	Not specified
PFS with	Details on progression-free survival (PFS) improvement need further clarification; the trial primarily highlighted improvements in overall survival
Usefulness Rating	4
Usefulness Explanation	Not specified
Toxicity Level	2
Toxicity Explanation	The treatment has a toxicity level of 2 out of 5 which means it is fairly low in toxicity. The most commonly reported side effects include fatigue, dizziness, nausea, and mouth irritation. Please remember, these side effects do not occur in everyone and can be managed with the help of your healthcare team. More research is needed to fully understand the long-term effects of this treatment. As it is not FDA-approved in the United States, one has to monitor carefully when and if the treatment becomes available depending on the approval in their country.

Notes: In a notable 2021 trial, Sativex, combined with temozolomide, demonstrated an increase in overall survival among glioblastoma patients, marking a promising advancement in the use of cannabinoid-based therapies for cancer treatment. These results suggest Sativex may possess anti-tumor properties in addition to its symptom management potential, warranting further research to fully understand its therapeutic benefits and mechanism of action in glioblastoma.

From Ben Williams Book: Not specified

Loading comments...